FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

March 12, 2026 updated by: Fulgent Pharma LLC.

A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The goal of this FID-007 Randomized, Multicenter, Open-label clinical trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) based on objective response rate. The main questions it aims to answer are:

  • To evaluate the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients based on Best Overall Response (BOR), Duration of Response (DoR), Disease Control Rate (DCR), Progression-Free Survival (PFS), and Overall Survival (OS).
  • To characterize the pharmacokinetics (PK) of FID-007 and its metabolites (6-α-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel) following administration of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic HNSCC.
  • To characterize the safety and tolerability of different dosing regimens of FID-007 in combination with Cetuximab in patients.

Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab (starting from Cycle 2, 500 mg/m2 intravenous [IV] infusion every 2 weeks on Days 1 and 15 of each 28-day cycle). Patients will receive FID-007 via IV infusion over 30 minutes at their assigned dose on Days 1, 8, and 15 of each 28-day cycle.

Patients will continue to receive Cetuximab and FID-007 until they meet the study drug discontinuation criteria.

Study Type

Interventional

Enrollment (Estimated)

46

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arkansas
      • Fayetteville, Arkansas, United States, 72703
        • Highlands Oncology - North Hills
    • California
      • Los Angeles, California, United States, 90033
        • USC/Norris Comprehensive Cancer Center and Hospital
    • Florida
      • Tampa, Florida, United States, 33612
        • Moffitt Cancer Center Magnolia Campus
    • Indiana
      • Fort Wayne, Indiana, United States, 46804
        • Fort Wayne Medical Oncology and Hematology
    • Texas
      • Dallas, Texas, United States, 75246
        • Texas Oncology - Baylor Charles A. Sammons Cancer Center
      • Tyler, Texas, United States, 75702
        • Texas Oncology - Northeast Texas Cancer & Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Ability to understand and willingness to provide informed consent before the start of any study-specific procedures.
  2. Age ≥18 years old.

  3. A diagnosis of recurrent or metastatic HNSCC at 1 of the following sites:

    1. Nasal/paranasal sinuses
    2. Nasopharynx (Epstein-Barr virus [EBV] negative only)
    3. Oral cavity
    4. Oropharynx
    5. Hypopharynx
    6. Larynx
  4. Disease progression after treatment with PD-L1-based immune checkpoint inhibitor at any time. This can be as monotherapy or in combination with chemotherapy.
  5. Measurable disease according to RECIST version 1.1.
  6. Adequate treatment washout period of ≥21 days or 5 half-lives, whichever is shorter, for prior chemotherapy, radiotherapy, hormonal therapy, biological therapy, or immunotherapy before the first dose of study drug administration. Note: Palliative radiation is permitted but not ≤7 days before the first dose of study drug.
  7. ECOG PS of 0 or 1.
  8. Recovery from any toxic effects of previous chemotherapy, targeted therapy, or radiotherapy as judged by the investigator to Grade ≤1 (except for alopecia) according to NCI CTCAE version 5.0.

  9. Adequate bone marrow and organ function defined as the following:

    Bone marrow function

    • Absolute neutrophil count ≥1500/mm3 (growth factor administration is not permitted ≤1 week before the screening assessment)
    • Platelet count ≥100,000/mm3 (platelet transfusion is not permitted ≤1 week before the screening assessment)
    • Hemoglobin ≥8 g/dL (criteria must be met without packed red blood cell transfusion ≤1 week before the screening assessment; chronic treatment with erythropoietin is permitted if the patient is on erythropoietin for ≥8 weeks)

    Blood clotting function

    • International normalized ratio (INR) ≤1.5 × upper limit of normal (ULN) and activated partial thromboplastin time ≤1.5 × ULN (except patients who are receiving therapeutic anticoagulation and whose INR should be within the therapeutic range)

    Renal function

    •Calculated clearance (using the Cockroft-Gault formula) ≥40 mL/min/1.73 m2. Actual body weight should be used for calculating creatinine clearance. For patients with a body mass index >30 kg/m2, lean body weight should be used instead

    Hepatic function

    • Total bilirubin ≤1.5 × ULN (patients with Gilbert's disease can have bilirubin >1.5 × ULN to <3 × ULN)
    • Aspartate aminotransferase/alanine aminotransferase ≤3 × ULN
  10. An estimated life expectancy of at least 3 months based on investigator judgment.
  11. Negative serum pregnancy test result at screening for female patients of childbearing potential.
  12. Willingness to abide by the contraceptive requirements in Appendix 1 of the protocol.

Exclusion Criteria:

  1. Known hypersensitivity to paclitaxel.
  2. EBV-positive nasopharyngeal cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, or squamous cell carcinoma of the salivary gland or skin, based on the patient's medical history.
  3. Received >1 prior line of anticancer therapy for recurrent or metastatic HNSCC. All patients must be previously treated with an immune checkpoint inhibitor either as monotherapy or in combination with chemotherapy. Patients treated with upfront combination chemo-immunotherapy followed by immunotherapy maintenance are considered to have received only 1 prior line of therapy. Chemotherapy given as part of treatment for locally advanced disease in the adjuvant or neoadjuvant setting is not considered a line of prior therapy for recurrent/metastatic disease. If the patient received prior treatment with Cetuximab, paclitaxel, or nab-paclitaxel in combination with radiation in the locally advanced setting and no relapse within 6 months of treatment discontinuation, enrollment is permitted if the treating physician believes that retreatment with Cetuximab or a taxane is a clinically reasonable option. However, patients who received these agents for recurrent or metastatic disease will be excluded.
  4. Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, that in the judgment of the investigator could compromise the patient's safety or the study data integrity.
  5. Preexisting sensory neuropathy of Grade >1 severity by NCI CTCAE version 5.0 criteria.
  6. Known history of uncontrolled HIV infection defined as CD4+ cells <350/mm3.
  7. Requirement of systemic steroids at daily doses >10 mg prednisone equivalent systemic exposure daily, including for control of symptoms.
  8. Use of any CYP2C8 and CYP3A4 inhibitor (eg, ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) or inducer (eg, rifampicin, carbamazepine, phenytoin, efavirenz, and nevirapine) in the previous 14 days before the first dose of study drug until the last PK sample is obtained in the study.
  9. Known brain metastasis. Note: Patients whose central nervous system metastases have been treated by surgery or radiotherapy, who are no longer on corticosteroids, and who are neurologically stable are eligible.
  10. Current or recent participation in a study of an investigational product in the prior 4 weeks. Note: Patients who have completed the treatment phase of an investigational study and have entered the follow-up phase of the investigational study may participate in FID-007-003 as long as it has been ≥4 weeks before the first dose of study drug.
  11. Pregnancy, breastfeeding, or plans to become pregnant during the study or within 24 weeks after the last dose of study drug (Appendix 1 of the protocol).
  12. Plans to donate/bank or retrieve eggs (ova, oocytes) during the study or within 24 weeks after the last dose of study drug (Appendix 1 of the protocol).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm A
FID-007 (75 mg/m2) plus Cetuximab (500 mg/m2)
Drug: FID007
Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
Other Names:
  • Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007
Active Comparator: Arm B
FID-007 (125 mg/m2) plus Cetuximab (500 mg/m2)
Drug: FID007
Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
Other Names:
  • Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
Time Frame: Through study completion, an average of 1 year
To evaluate the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic HNSCC based on Objective Response Rate (ORR).
Through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
BOR assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
Time Frame: Through study completion, an average of 1 year
Best Overall Response (BOR) measures the changes in tumor mass, growth (progression) or shrinkage (response) using the RECIST criteria.
Through study completion, an average of 1 year
Duration of Response (DoR) measurement
Time Frame: Through study completion, an average of 1 year
The length of time that a tumor continues to respond to treatment without the cancer growing or spreading will be recorded.
Through study completion, an average of 1 year
Progression-free Survival (PFS) measurement
Time Frame: Through study completion, an average of 1 year
The length of time to either radiological confirmed progression or death from any cause will be recorded.
Through study completion, an average of 1 year
Overall Survival (OS) measurement
Time Frame: Through study completion, an average of 1 year
The length of time to death from any cause will be recorded.
Through study completion, an average of 1 year
Disease Control Rate (DCR) analysis
Time Frame: Through study completion, an average of 1 year
The percentage of patients with advanced HNSCC who have achieved complete response, partial response and stable disease to different treatment regimens will be calculated.
Through study completion, an average of 1 year
Adverse Events (AEs) graded according to the CTCAE version 5.0
Time Frame: Through study completion, an average of 1 year
Safety and tolerability of different dosing regiments will be assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Through study completion, an average of 1 year
Vital Signs safety assessments
Time Frame: Through study completion, an average of 1 year
Vital signs measurements include body temperature in Fahrenheit, respiratory rate, heart rate, and systolic and diastolic blood pressure measurements. Any confirmed, clinically significant abnormal vital sign measurements must be recorded as AEs.
Through study completion, an average of 1 year
Clinical Laboratory safety assessments
Time Frame: Through study completion, an average of 1 year
Routine hematology, chemistry, and urinalysis to be performed at visits. Any confirmed, clinically significant abnormal laboratory results must be recorded as AEs.
Through study completion, an average of 1 year
ECGs safety assessment
Time Frame: Through study completion, an average of 1 year
12-lead Electrocardiograms (ECGs) should be performed before the start and after the end of FID-007 infusion. An assessment of normal, clinically significant or abnormal, not clinically significant will be recorded.
Through study completion, an average of 1 year
Area Under the Plasma Concentration Versus Time Curve (AUC) of FID-007
Time Frame: Cycle 2 (each cycle is 28 days)
Application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient.
Cycle 2 (each cycle is 28 days)
Peak Plasma Concentration (Cmax)
Time Frame: Cycle 2 (each cycle is 28 days)
Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
Cycle 2 (each cycle is 28 days)
Terminal/elimination half-life (t1/2)
Time Frame: Cycle 2 (each cycle is 28 days)
Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
Cycle 2 (each cycle is 28 days)
Clearance (CL)
Time Frame: Cycle 2 (each cycle is 28 days)
Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
Cycle 2 (each cycle is 28 days)
Volume of Distribution (Vd)
Time Frame: Cycle 2 (each cycle is 28 days)
Application of pharmacokinetic parameters to the safe and effective therapeutic management of drugs in an individual patient.
Cycle 2 (each cycle is 28 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fulgent Pharma LLC.

Investigators

  • Principal Investigator: Fulgent Clinical Sites, Fulgent Pharma LLC.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 10, 2024

Primary Completion (Actual)

December 31, 2025

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

March 12, 2024

First Submitted That Met QC Criteria

March 19, 2024

First Posted (Actual)

March 27, 2024

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 12, 2026

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FID-007-003

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Head and Neck Squamous Cell Carcinoma

Clinical Trials on FID007

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe